Acute severe hypocalcaemia after initiation of a selective RET-inhibitor in medullary thyroid cancer

• Published in: Endocrine oncology Vol. 5; no. 1; p. e240060
• Main Authors: Cheng, Leslie, Ghaznavi, Syeda Khadijah, Stevens, Jessica, Hoy, Sonja, Wong, Kee Howe, Malik, Tass, Newbold, Kate, Morganstein, Daniel
• Format: Journal Article
• Language: English
• Published: England Bioscientifica Ltd 01.01.2025; Bioscientifica
• Subjects: Case Report; hypocalcaemia; medullary thyroid cancer; ret-inhibitor; tyrosine kinase inhibitor; medullary thyroid cancer; tyrosine kinase inhibitor; hypocalcaemia; RET-inhibitor
• ISSN: 2634-4793; 2634-4793
• DOI: 10.1530/EO-24-0060

Medullary thyroid cancer (MTC) is a rare subtype of thyroid cancer originating from parafollicular C-cells of the thyroid. Tyrosine kinase inhibitors are used to treat patients with advanced MTC. Selpercatinib is a highly selective RET inhibitor used in the treatment of advanced RET-mutated MTC, hav...